Conference Program*

All times listed are Sedona, AZ Mountain Time (MT)

View this event in your time zone

The IOVC Program Book is hands free!

Download the full IOVC Program Book for use on-site! We've gone contact-free in efforts to maintain physical distancing on-site and to keep each other safe.

Download the Program Book

Thursday, November 4

Welcome Reception
Porch Patio
7:30-9:30 p.m.

Friday, November 5

Badge Pickup
7:30 a.m.-5 p.m.
Canyon Ballroom Foyer

Breakfast
7:30-8:30 a.m.
Canyon Ballroom Foyer

Scientific Session 1: Novel Payloads and Mechanisms of Action 1
Chairpersons: John Bell, PhD, and Grant McFadden, PhD
8:30-10:08 a.m.

• David Stojdl, PhD
  8:30-8:55 a.m.

• Leslie Sharp, PhD, OncoMyx Therapeutics
  Multi-armed myxoma virus demsonstrates activity in preclinical models
  8:55-9:20 a.m.

• Oral Abstract 1
  Divya Ravirala, PhD, University of Houston
  Co-delivery of Novel bi-Specific and tri-Specific Engagers by an Amplicon Vector Augments the Therapeutic Effect of a HSV-based Oncolytic Virotherapy
  9:20-9:32 a.m.

• Oral Abstract 2
  Nikolas Martin, PhD, Ottawa Hospital Research Institute
  An oncolytic vaccinia virus encoding virus-like-particles and self-amplifying RNA replicons: Teaching new tricks to an old virus 
  9:32-9:44 a.m.

• Oral Abstract 3
  Bart Spiesschae, DVM, PhD, ViraTherapeutics GmbH
  Lymphotoxin-α-armed oncolytic VSV-GP synergizes with SMAC mimetics to induce enhanced tumor cell death and regression
  9:44-9:56 a.m.

• Oral Abstract 4, 
  John Christie, MS, Arizona State University School of Life Sciences
  Delivery and Efficacy of LIGHT-armed Myxoma Virus in a Syngeneic Lung Metastatic Murine Osteosarcoma
  9:56-10:08 a.m.

Coffee Break
10:08-10:30 a.m.

Scientific Session 2: Novel Payloads and Mechanisms of Action 2
Chairpersons: John Bell, PhD, and Grant McFadden, PhD
10:35 a.m.-11:56 a.m.

• Leonard Seymour, PhD, University of Oxford
  Arming oncolytic DNA viruses to improve their anticancer impact
  10:30-10:55 a.m.

• Balveen Kaur, PhD, McGovern Medical School
  Oncolytic Viral therapy signaling NOTCH
  10:55-11:20 a.m.

• Oral Abstract 5
  Haifei Jiang, PhD, Mayo Clinic
  Herpesviral Combination Therapy For Targeting Both Cancer Cells And Cancer Associated Stromal Cells
  11:20-11:32 a.m.

• Oral Abstract 6
  Flurin Caviezel, MSc, University of Oxford
  Targeting the Extracellular Matrix to Overcome Immunosuppression Using Bi-Specifics Delivered by Oncolytic Viruses
  11:32-11:44 a.m.

• Oral Abstract 7
  Emanuele Sasso, PhD, University of Naples Federico
  Arming Oncolytic Herpes Virus with Adenosine Deaminase Enzyme for Clearance of Immunosuppressive Tumor Adenosine
  11:44-11:56 a.m.

Lunch
11:56 a.m.-12:55 p.m.

Scientific Session 3: Novel Combinations and Mechanisms of Action
Chairpersons: Martine Lamfers, PhD, and Samuel Rabkin, PhD
12:55-2:33 p.m.

• Kevin Harrington, PhD, The Institute of Cancer Research, London
  Mechanistic studies of drug-virus combinations reveal unexpected immunotherapeutic potential
  12:55-1:20 p.m.

• Chae-Ok Yun, PhD, GeneMedicine Co., Ltd.
  Tumor-targeted systemic delivery of oncolytic adenoviruses using nanocarrier platform
  1:20-1:45 p.m.

• Oral Abstract 8
  Lorella Tripodi, European School of Molecular Medicine (SEMM)
  Gut microbiome affects oncolytic adenovirus-mediated immunogenic cell death in a melanoma mouse model  
  1:45-1:57 p.m.

• Oral Abstract 9
  Miriam Valenzuela, MSc, UNMHSC
  Tumor Necrosis Factor α plays multiple negative roles during oncolytic therapy both inhibiting systemic efficacy and exacerbating immune mediated toxicities   
  1:57-2:09 p.m.

• Oral Abstract 10
  Guido Wollmann, MD, Medical University Innsbruck
  A Modular Self-Adjuvanting Cancer Vaccine Combined With An Oncolytic Vaccine Induces Potent Antitumor Immunity  
  2:09-2:21 p.m.

• Oral Abstract 11
  Zaid Taha, MSc, Ottawa Hospital Research Institute, University of Ottawa
  Evaluation of Viral Sensitizing Antibody-Drug Conjugate (ADC) and Oncolytic Virus Combination Regimen in Novel Murine Models of HER2+ Cancer  
  2:21-2:33 p.m.

Coffee Break
2:33-2:45 p.m.

Scientific Session 4: Novel Combinations and Mechanisms of Action 2
2:45-4:11 p.m.

• Alan Melcher, PhD, The Institute of Cancer Research, London
  Oncolytic Herpes Virus and BRAF Inhibitor Therapy for Melanoma: The Role and Application of CD4 T Cell Signaling Dynamics
  2:45-3:10 p.m.

• Richard Vile, PhD
  3:10-3:35 p.m.

• Oral Abstract 12
  Jahanara Rajwani, University of Calgary
  Oncolytic Virus Infection of Non Cancer Cells Improves Antitumour Immunity by Increasing Tumour-Antigen Specific T Cell Generation in the Lymph Node  
  3:35-3:47 p.m.

• Oral Abstract 13
  Matthew Mullarkey, MD, McGovern Medical School, UTHSC
  Oncolytic HSV-P10 and Targeting of Glycolysis and Oxidative Phosphorylation as a Potential Therapy in the Treatment of Glioblastoma    
  3:47-3:59 p.m.

• Oral Abstract 14
  Molly Holbrook, University of North Carolina at Charlotte
  Screening of FDA-Approved Drug Library for Combinatorial Treatment of Pancreatic Cancer Cells with Oncolytic Vesicular Stomatitis Virus
  3:59-4:11 p.m.

Scientific Session 5: Clinical Trials 1
Chairpersons: E. Antonio Chiocca, M.D., Ph.D., FAANS, and Chae-Ok Yun, PhD
4:11-5:26 p.m.

• E. Antonio Chiocca, MD, PhD, FAANS, Harvard Medical School
  First In Human Clinical Trials of New Oncolytic Virus Expressing ICP34.5 for Glioblastoma
  4:11-4:36 p.m.

• Joselle Cook, MD, Mayo Clinic
  Clinical Activity of Systemic VSV-IFNβ-NIS Oncolytic Virotherapy in Patients with Hematologic Malignancies
  4:36-5:01 p.m.

• Tomoki Todo, PhD, University of Tokyo
  Clinical development and approval of oncolytic herpes virus G47∆
  5:01-5:26 p.m.

Dinner
6-9:45 p.m.
Steakhouse 89
2620 W. State Rte 89A
Sedona, AZ 86336
SHUTTLES PROVIDED

Satuday, November 6

Badge Pickup
7:30 a.m.-5 p.m.
Canyon Ballroom Foyer

Breakfast
7:30-8:30 a.m.
Canyon Ballroom Foyer

Scientific Session 6: Novel Viral Platforms 1
Chairperson: Noriyuki Kasahara, MD, PhD
8:30-9:56 a.m.

• Stephen Russell, MD, PhD
  8:30-8:55 a.m.

• Oral Abstract 15
  Sara Feola, University of Helsinki
  A Novel Immunopeptidomic-Based Pipeline for the Generation of Personalized Oncolytic Cancer Vaccines  
  8:55-9:07 a.m.

• Oral Abstract 16
  Karol Budzik, PhD, Mayo Clinic
  Development and Characterization of a Foamy Virus-Based Oncolytic Replicating Retroviral Vector
  9:07-9:19 a.m.

• Oral Abstract 17
  Liang Deng, MD, PhD, Memorial Sloan Kettering Cancer Center
  TARGETING REGULATORY T CELLS AND EXHAUSTED T CELLS BY A SECOND-GENERATION RECOMBINANT MODIFIED VACCINAI VIRUS ANKARA  
  9:19-9:31 a.m.

• Yuman Fong, MD, City of Hope Medical Center
  Redesigning the Pox Virus for Oncolytic Therapy
  9:31-9:56 a.m.

Coffee Break
9:56-10:15 a.m.

Scientific Session 7: Novel Platforms 2
Chairperson: Stephen J. Russell, MD, PhD
10:15 a.m.-11:16 a.m.

• Autumn Schulze, PhD, Mayo Clinic
  Synthetic Infectious RNA-Based Oncolytic Immunotherapy
  10:15-10:40 a.m.

• Oral Abstract 18
  Shaun Xialiu Zhang, MD, PhD, University of Houston
  Novel Strategies to Modify an Oncolytic HSV for Systemic Delivery  
  10:40-10:52 a.m.

• Oral Abstract 19
  Alexander Haddad, MD, UCSF
  A Synthetic Novel Replicating Retroviral Gene Therapy Platform for the Treatment of Glioblastoma
  10:52-11:04 a.m.

• Oral Abstract 20
  Velia Penza, MS, Mayo Clinic
  Deletion of the polycytidine (polyC) tract in oncolytic miRNA-detargeted Mengovirus increases its therapeutic efficacy in a murine multiple myeloma model
  11:04-11:16 a.m.

Lunch
11:16 a.m.-11:40 a.m.

Keynote Speaker Session
Chairperson: Stephen J. Russell, MD, PhD
11:40 a.m.-1:05 p.m.

• Announcement of Golden Virus Awards
  11:40 a.m.-12 p.m.

• Introduction to Keynote Speaker
  12-12:05 p.m.

• Larry Corey, MD, Fred Hutchinson Cancer Research Center
  The Trek Toward COVID-19 Vaccines: How We Got There and What's Left to Accomplish
  12:05-1:05 p.m.     

Afternoon Activities
1:05-6 p.m.

Working Dinner
6:30-7 p.m.
Provided

Special Session
Chairperson: Kah Whye Peng, PhD, and David Stojdl, PhD
7-9:08 p.m.

• Paul Peter Tak, MD, PhD, Candel Therapeutics
  Leveraging Viral Oncolytic Immunotherapy Platform To Tip The Balance In Favor Of The Immune System  
  7-7:20 pm

• David Krige, PhD, Psioxus
  Dose-dependent and Persistent Increases in Inflammatory Cytokines in Patients with Metastatic/Advanced Epithelial Cancer Following Treatment with Novel T-SIGn Vectors  
  7:20-7:40 pm

• Steve Thorne, PhD, Kalivir Therapeutics
  The VET platform; re-targeting oncolytic vaccinia virus to tumors through expression of chemokine receptors
  7:40-8 pm

• James Burke, MD, CG Oncology
  CG0070 a GM-CSF expression, tumor selective oncolytic adenovirus: Clinical Program Revie
  8-8:20 pm

• Rianna Vandergaast, Imanis Life Sciences
  Using the IMMUNO-COV Clinical Assay for SARS-CoV-2-Neutralizing Antibodies to Track Titer Declines in Individuals Following Vaccination
  8:20-8:32 pm

• Edward Kennedy, PhD, Oncorus Inc.
  Systemic Intravenous Synthetic RNA Virus Immunotherapy for the Repeat Treatment of Cancer
  8:32-8:44 pm

• Steve Potts, PhD, MBA, OncoMyx Therapeutics
  Benefits of a systemic-delivered, multi-armed non-human pathogen, myxoma virus, against solid and heme cancers
  8:44-8:56 pm

• Zane Yang, MD, Denovo Biopharma
  A novel precision medicine approach to advance Toca 511 gene therapy
  8:56-9:08 pm

Sunday, November 7

Badge Pickup
7:30 a.m.-5 p.m.
Canyon Ballroom Foyer

Breakfast
7:30-8:30 a.m.
Canyon Ballroom Foyer

Scientific Session 8: Clinical Trials 2
8:30-9:56 a.m.

• Rob Coffin, PhD, Replimune Inc.
  Next Generation Oncolytic HSV
  8:30-8:55 a.m.

• Helen Gogas, MD, PhD, National and Kapodistrian University of Athens
  Amgen Phase 3 T-Vec Melanoma Trial
  8:55-9:20 a.m.

• Oral Abstract 21
  Praveen Bommaredy, PhD, Replimune Inc.
  Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1 and RP2) alone and in combination with nivolumab in cancer patients indicate potent immune activation 
  9:20-9:32 a.m.

• Oral Abstract 22
  Shruthi Naik, PhD, Mayo Clinic
  SAFETY AND EFFICACY OF NEOADJUVANT INTRAVESICAL ONCOLYTIC MV-NIS IN PATIENTS WITH UROTHELIAL CARCINOMA
  9:32-9:44 a.m.

• Oral Abstract 23
  Guy Ungerechts, MD, PhD, National Center for Tumor Diseases Heidelberg
  Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Immune Cell Activity in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
  9:44-9:56 a.m.

Coffee Break
10-10:30 a.m.

Scientific Session 9: Clinical Trials 3
10:30 a.m.-12:08 p.m.

• Maciej S. Lesniak, MD, Northwestern Feinberg School of Medicine
  Neural Stem Cell Delivery of Oncolytic Virotherapy for Glioma
  10:30-10:55 a.m.

• Evanthia Galanis, MD, Mayo Clinic
  First in human Testing of Measles Virus Infected Mesenchymal Stem Cells
  10:55-11:20 a.m.

• Oral Abstract 24
  Adel Samson, PhD, University of Leeds
  Neoadjuvant Oncolytic Pexa Vec for Patients with Colorectal Cancer Liver Metastases  
  11:20-11:32 a.m.

• Oral Abstract 25
  Parker Dryja, UNMHSC
  Altered Arginine Metabolism within the Tumor Microenvironment Inhibits Oncolytic Myxoma Virus Replication Preventing Effective Therapy  
  11:32-11:44 a.m.

• Oral Abstract 26
  Miriam Bazan-Peregrino, DPhil, VCN Biosciences
  Oncolytic Adenovirus VCN-01 Targeting the Dysfunctional Rb Pathway Is an Encouraging Therapy Against Retinoblastoma
  11:44-11:56 a.m.

• Oral Abstract 27
  James Burke, MD, Moffit Cancer Center
  CORE1: Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)  
  11:56 a.m.-12:08 p.m.

Lunch
12:08-1:08 p.m.

Virtual Poster Presentations
1-3:30 p.m.

Coffee Break
3:30-3:55 p.m.

The Great Debate
Moderator: Stephen J. Russell, MD, PhD

• Announcement of Conrad Award Winners
  3:55-4 p.m.

• John Bell vs. Noriyuki Kashara
  Complex large viruses are superior to small, elegant viruses
  4-5:30 p.m.

Farewell Dinner
7-9:30 p.m.
Canyon Ballroom

*Program subject to change.